Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520
By
Published: Sept 10, 2015 7:30 a.m. ET
PASADENA, Calif., Sep 10, 2015 (BUSINESS WIRE) -- Arrowhead Research Corporation ARWR, +3.06% a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation starting at 11:00 a.m. EDT to discuss ARC-520, its candidate for the treatment of chronic hepatitis B infection. During the event, Arrowhead management and a panel of key opinion leaders will discuss results of the Heparc-2001 Phase 2a study and results of a nonclinical study conducted in 9 chimpanzees chronically infected with hepatitis B virus.
Guest speakers at the event include:
Robert G. Gish, M.D.
Medical Director, Hepatitis B Foundation
Clinical Professor of Medicine, University of Nevada, Las Vegas
Senior Medical Director, St. Joseph’s Hospital and Medical Center
Clinical Professor of Medicine (Consultant), Stanford Hospital and Medical Center
Stephen A. Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Head of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory
Director of WHO Collaborating Centre for Virus Reference and Research
Robert E. Lanford, PhD
Director of Southwest National Primate Research Center (SNPRC)
Scientist, Virology and Immunology and SNPRC, Texas BioMedical Research Institute
A live and archived version of the webcast, including presentation slides, will be available on the events section of the Company’s website at ir.arrowheadresearch.com/events.cfm. To access an audio only version of the live presentation, dial 855-215-6159 toll-free from the U.S. or 315-625-6887 for international callers and enter Conference ID 19541930.
By
Published: Sept 10, 2015 7:30 a.m. ET
PASADENA, Calif., Sep 10, 2015 (BUSINESS WIRE) -- Arrowhead Research Corporation ARWR, +3.06% a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation starting at 11:00 a.m. EDT to discuss ARC-520, its candidate for the treatment of chronic hepatitis B infection. During the event, Arrowhead management and a panel of key opinion leaders will discuss results of the Heparc-2001 Phase 2a study and results of a nonclinical study conducted in 9 chimpanzees chronically infected with hepatitis B virus.
Guest speakers at the event include:
Robert G. Gish, M.D.
Medical Director, Hepatitis B Foundation
Clinical Professor of Medicine, University of Nevada, Las Vegas
Senior Medical Director, St. Joseph’s Hospital and Medical Center
Clinical Professor of Medicine (Consultant), Stanford Hospital and Medical Center
Stephen A. Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Head of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory
Director of WHO Collaborating Centre for Virus Reference and Research
Robert E. Lanford, PhD
Director of Southwest National Primate Research Center (SNPRC)
Scientist, Virology and Immunology and SNPRC, Texas BioMedical Research Institute
A live and archived version of the webcast, including presentation slides, will be available on the events section of the Company’s website at ir.arrowheadresearch.com/events.cfm. To access an audio only version of the live presentation, dial 855-215-6159 toll-free from the U.S. or 315-625-6887 for international callers and enter Conference ID 19541930.
